The city of Orlando, Florida, currently has 15 active clinical trials seeking participants for Alzheimer's Disease research studies.
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerabili... Read More
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
02/06/2024
Locations: Synexus Clinical Research, Orlando, Florida
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
Recruiting
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
11/21/2023
Locations: Eisai Site #2, Orlando, Florida
Conditions: Alzheimer's Disease
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
Recruiting
The primary purpose of this long-term follow-up study is to assess the long-term safety profile of APOE4 homozygote participants who were administered gene therapy (LX1001) for the treatment of Alzheimer's disease in Study LX100101. A secondary objective is to assess the biomarker as shown by the conversion of CSF APOE isoforms from APOE4 to APOE2-APOE4. Additional secondary outcomes include amyloid PET scan, CSF markers (including Aβ42, Aβ42/Aβ40 ratio T--tau, and P-tau), and quantitative MRI (... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
11/13/2023
Locations: PPD- Orlando Research Unit, Orlando, Florida
Conditions: Alzheimer Disease